Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mytrex Health TechnologiesROCO:4431 +2.50%74 Return-on-Tangible-Equity is 1.05% as of Jun. 2026, which is 62% above its 10-year median of 0.65. GuruFocus rates ROCO:4431 with a GF Score™ of 74/100 and a GF Value™ of NT$28.80 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 2,977 Industrial Products companies, Mytrex Health Technologies ranks worse than 77.76% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Mytrex Health Technologies's annualized net income for the quarter that ended in Jun. 2026 was NT$5 Mil. Mytrex Health Technologies's average shareholder tangible equity for the quarter that ended in Jun. 2026 was NT$502 Mil. Therefore, Mytrex Health Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 1.05%.
The historical rank and industry rank for Mytrex Health Technologies's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:4431'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -14.89 Med: 0.65 Max: 54.07
Current: -1.05
During the past 13 years, Mytrex Health Technologies's highest Return-on-Tangible-Equity was 54.07%. The lowest was -14.89%. And the median was 0.65%.
ROCO:4431's Return-on-Tangible-Equity is ranked worse than 77.76% of 2977
companies
in the Industrial Products industry
Industry Median: 6.99
vs ROCO:4431: -1.05
Mytrex Health Technologies (ROCO:4431) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Mytrex Health Technologies Return-on-Tangible-Equity Related Terms
Mytrex Health Technologies Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mytrex Health Technologies Return-on-Tangible-Equity Chart
ROCO:4431 vs GEV, ETN, PH: Return-on-Tangible-Equity Comparison
For the Specialty Industrial Machinery subindustry, Mytrex Health Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mytrex Health Technologies Return-on-Tangible-Equity vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Mytrex Health Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Mytrex Health Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1.05% mean?
Mytrex Health Technologies (ROCO:4431) has a Return-on-Tangible-Equity of 1.05% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mytrex Health Technologies and its competitors. This is 62% above median its historical median of 0.65. According to the industry distribution chart, Mytrex Health Technologies ranks #2315 out of 2977 companies in the Industrial Products industry, placing it in the top 77.8%.
Is Mytrex Health Technologies' Return-on-Tangible-Equity too high?
Mytrex Health Technologies' current Return-on-Tangible-Equity of 1.05% is 62% above median its 10-year median of 0.65. The Industrial Products industry median Return-on-Tangible-Equity is 6.99. Mytrex Health Technologies' value of 1.05% is 85% below this industry median. Based on the distribution chart, Mytrex Health Technologies ranks #2315 out of 2977 companies in the Industrial Products industry, which is in the bottom quartile relative to peers. Overall, Mytrex Health Technologies has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mytrex Health Technologies' Return-on-Tangible-Equity compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Mytrex Health Technologies ranks #2315 out of 2977 companies for Return-on-Tangible-Equity. This places Mytrex Health Technologies in the lower half of its industry. The industry median Return-on-Tangible-Equity is 6.99. Mytrex Health Technologies' value of 1.05% is 85% below this benchmark. While the company's 10-year median is 0.65 vs. the industry median of 6.99, Mytrex Health Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for an Industrial Products company?
The median Return-on-Tangible-Equity among Industrial Products companies is 6.99, based on 2,977 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mytrex Health Technologies's current Return-on-Tangible-Equity of 1.05% is 85% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mytrex Health Technologies and its competitors. For the Industrial Products industry, the median Return-on-Tangible-Equity is 6.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mytrex Health Technologies's current Return-on-Tangible-Equity is 1.05%, which is 62% above median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mytrex Health Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mytrex Health Technologies (ROCO:4431) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.80, compared to a current price of NT$20.50 — trading 28.8% below its estimated fair value. The current Return-on-Tangible-Equity is 1.05%, which is 62% above median its 10-year median of 0.65 and 85% below the Industrial Products industry median of 6.99. Mytrex Health Technologies' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Mytrex Health Technologies (ROCO:4431), the current Return-on-Tangible-Equity is 1.05% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mytrex Health Technologies (ROCO:4431) Overvalued in 2026?
Based on GuruFocus' analysis, Mytrex Health Technologies stock appears to be undervalued.
The current stock price of NT$20.50 is trading 28.8% below its estimated GF Value™ of NT$28.80.
GuruFocus considers Mytrex Health Technologies to be Modestly Undervalued.
Key valuation signals for ROCO:4431:
Return-on-Tangible-Equity: 1.05% (62% above median its 10-year median of 0.65)
GF Value™: NT$28.80 vs. price of NT$20.50 (28.8% below fair value)
Industry Position: 85% below the Industrial Products median (#2315 of 2977)
No single metric tells the full story. See the ROCO:4431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mytrex Health Technologies Inc is a Taiwan-based company engaged in the manufacturing of non-woven materials and special medical supplies. It is engaged in the development and production of melt-blown products for the protection of the environment and human health. The company offers products ranging from medical to industrial filtration materials such as various types of filtration media, lab coats or outfits, cabin filtration, vacuum cleaner filter bags, and special medical supplies. Its product categories include meltdown, mammoth bedding, and specialized medical supplies like balloon catheters and coronary stents.
74GF Score
Get the complete analysis for ROCO:4431
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4431 has been successfully added to your 
